Identification of potential core genes in hepatoblastoma via bioinformatics analysis

Hepatoblastoma is the childhood liver cancer. Profound efforts have been made to illuminate the pathology, but the molecular mechanisms of hepatoblastoma are still not well understood. To identify the candidate genes in the carcinogenesis and progression of hepatoblastoma, microarray dataset GSE131329 was downloaded from Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) were identified, and pathway and Gene Ontology (GO) enrichment analysis were performed. The protein-protein interaction network (PPI), module analysis, target gene - miRNA regulatory network and target gene - TF regulatory network were constructed and analyzed. A total of 996 DEGs were identified, consisting of 499 up regulated genes and 497 down regulated genes. The pathway and Gene Ontology (GO) enrichment analysis of the DEGs include proline biosynthesis, superpathway of tryptophan utilization, chromosome organization and organic acid metabolic process. Twenty-four hub genes were identified and biological process analysis revealed that these genes were mainly enriched in cell cycle, chromosome organization, lipid metabolic process and oxidation-reduction process. Validation of hub genes showed that TP53, PLK1, AURKA, CDK1, ANLN, ESR1, FGB, ACAT1, GOT1 and ALAS1 may be involved in the carcinogenesis, invasion or recurrence of hepatoblastoma. In conclusion, DEGs and hub genes identified in the present study help us understand the molecular mechanisms underlying the carcinogenesis and progression of hepatoblastoma, and provide candidate targets for diagnosis and treatment of hepatoblastoma.


Introduction
Hepatoblastoma is a highly complex and uncommon malignant type of liver cancer appears in infants and children [Kremer et al 2014], and accounting for just over 1% of pediatric cancers [Spector and Birch, 2012]. Despite significant advancements in treatments, including surgery [Busweiler et al 2017], chemotherapeutic [Hiyama et al 2016] and liver transplantation [Cruz Jr et al 2013], the survival rate of patients with hepatoblastoma has not sufficiently improved. The high rates of recurrence and metastasis in patients with hepatoblastoma require the critical advancement of novel diagnostic strategies and therapeutic agents to enhance patient prognosis. As the molecular mechanisms of hepatoblastoma tumorigenesis and development are not yet fully understood, there remains to be a number of unsolved issues in the diagnosis and treatment of hepatoblastoma. Therefore, it is important to identify new biomarkers and pathways linked with tumorigenesis and patient prognosis, in order to help resolve the suitable basic molecular mechanisms, and to help discover novel diagnostic and prognostic markers, and therapeutic targets.
Altered expression and mutations of genes, and signalling pathways are associated in the advancement and development of hepatoblastoma. Genes such as β -catenin [Koch et al. 1999], Axin [Miao et al. 2003], SOCS-1 [Nagai et al. 2003], lipin 1 [Ishimoto et al. 2009] and MT1G [Sakamoto et al. 2010] were linked with development of hepatoblastoma. Signalling pathways such as PI3K/Akt, ERK and p38 signaling pathways [Cui et al. 2016], MAPK signaling pathways [Yuan et al. 2013], notch signalling pathway [Aktaş et al. 2010], Wnt/β catenin signalling pathway [Cui et al. 2020] and EGFR-ASAP1 signaling pathway [Ranganathan et al. 2016] were responsible for progression hepatoblastoma. Hepatoblastoma remains a require disease to treat, and more investigations are required to develop the understanding of the underlying molecular mechanisms to diagnose genes and signaling for the progression of new therapies. Therefore, the pathogenesis of hepatoblastoma warrants further studies.
With the accelerated advancement of microarray technology, some high throughput platforms for analysis of gene expression are extensively used to examine the differentially expressed genes (DEGs) during cancer progression [Ma et al. 2019]. Many gene expression profiling studies on hepatoblastoma have been implemented using microarray technology and identified many up

Construction of the PPI network and module analysis
The PPI network was constructed based on all the DEGs (up and down regulated genes) using IID (Integrated Interactions Database) from a well known online server (http://iid.ophid.utoronto.ca) [ [Wang et al 2012], were calculated using the Network Analyzer plugin in Cytoscape software (http://apps.cytoscape.org/apps/NetworkAnalyzer). In addition, PEWCC1 (http://apps.cytoscape.org/apps/PEWCC1) in Cytoscape software was used to analyze the most significant module, with the threshold value of 5 [Zaki et al 2013].

Construction of target genes -miRNA regulatory network
The miRNAs (microRNA) that can regulate the up and down regulated genes were predicted using the miRNet database (https://www.mirnet.ca/) [Fan and Xia, 2018] with default significant parameters. Only the interaction relationships can be predicted by ten common algorithms, including TarBase [Li et al. 2014], were included to construct the target gene-miRNA regulatory network using the Cytoscape software.

Construction of target genes -TF regulatory network
The TFs (transcription factors) that can regulate the up and down regulated genes were predicted using the NetworkAnalyst database (https://www.networkanalyst.ca/) [Zhou et al 2019] with default significant parameters. Only the interaction relationships can be predicted by ENCODE (http://cistrome.org/BETA/) [Wang et al 2013],were included to construct the target gene-TF regulatory network using the Cytoscape software. UALCAN (http://ualcan.path.uab.edu/analysis.html) [Chandrashekar et al 2017] is a website that offers an online validation of survival biomarkersand analyzes the overall survival (OS) of patients with high and low expression of certain genes. In our investigation, up and down regulated hub genes were detected, and a survival curve was drawn. The log-rank p-value was calculated. And the UALCAN [Chandrashekar et al 2017] platform was applied to further verify the expression level of up and down regulated hub genes between hepatoblastoma and normal samples from The Cancer Genome Atlas (TCGA) portal. Next, UALCAN [Chandrashekar et al 2017] platform was applied to further verify the expression level of up and down regulated hub genes from normal to all stages of hepatoblastoma from The Cancer Genome Atlas (TCGA) portal. Mutaion analysis of up and down regulated hub gens was performed by cBioPortal online platform (http://www.cbioportal.org) [Gao et al 2013]. We also evaluated the protein expression of up and down regulated hub genes by using the human protein atlas (HPA, www.proteinatlas.org) [Uhlen et al 2010] database considering that gene expression was not always consistent with its protein level. Receiver operating characteristic (ROC) analysis was conducted by using the generalized linear model (GLM) in machine learning algorithms [Robinet al. 2011] to show the potential diagnostic and prognostic value of up and down regulated hub genes. P<0.05 was considered to indicate a statistically significant difference. Up and down regulated hub genes was quantified using real-time PCR. Total RNA was isolated from cultured Hep G2 and normal liver cells using a TRI Reagent® (Sigma, USA). RNA was then reverse transcribed into cDNA according to the instructions of a FastQuant RT kit (with gDNase; Tiangen Biotech Co., Ltd.). RT-PCR was performed using a QuantStudio 7 Flex real-time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The reaction conditions were as follows: predenaturation at 95 °C for 10 min and 40 cycles of denaturation at 95 °C for 10 sec, annealing at 60 °C for 20 sec and extension at 72 °C for 34 sec.

Validation of hub genes
β -actin was used as the internal reference for up and down regulated hub genes. The primers for up and down regulated hub genes are listed in Table 1. The 2 -ΔΔCt technique was engaged to measure the ratio of the relative expression of a target gene in the experimental group to that in the control group with the following formulas: Δ Δ Ct = Δ Ct experimental group -Δ Ct control group and Δ Ct = Ct target gene -Ct internal reference. Ct was the amplification cycle. Three separate experiments were conducted [Livak and Schmittgen, 2001]. The immune infiltration analysis for up and down regulated hub genes have been conducted with the scatter plot in TIMER (https://cistrome.shinyapps.io/timer/) [Li et al. 2017] is a RNA-Seq expression profiling database from The Cancer Genome Atlas (TCGA) portal. Immune infiltration analysis was used to check the immune infiltrates (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) across hepatoblastoma.

Data pre-processing
Gene expression profile (GSE131329) was collected from the GEO database. A total of 67 samples included 53 hepatoblastoma tissues samples and 14 noncancerous liver tissue samples. The dataset was then performed normalization and batch effect correction ( Fig. 1A and 1B).
down regulated target genes were enriched in peroxisome, biological oxidations, lipid binding and metabolic pathways.

Construction of target genes -TF regulatory network
We constructed a target gene -TF regulatory network, and the network is shown in Fig. 13 and Fig. 14, which illustrates that certain TFs play important roles in regulating up and down regulated genes. In Fig. 13, nodes with greater degrees tend to be up regulated target genes. In this network, DCDC2 was targeted by the 121 TFs (ex, KLF9), WFS1 was targeted by the 120 TFs (ex, TFDP1), ERCC2 was targeted by the 117 TFs (ex, ZNF580), DLX5 was targeted by the 107 TFs (ex, MXD3) and CCNB1 was targeted by the 105 TFs (ex, SMAD5) are listed in Table 8. These up regulated target genes were enriched in generation of neurons, metabolism of proteins, gene expression, embryo development and cell cycle. In Fig. 14, nodes with greater degrees tend to be down regulated target genes. In this network, MASP2 was targeted by the 115 TFs (ex, ATF3), OTC was targeted by the 82 TFs (ex, YY1), ACMSD was targeted by the 76 TFs (ex, MYBL2), AGXT was targeted by the 76 TFs (ex, MBD4) and SLC15A1 was targeted by the 76 TFs (ex, HNF4G) are listed in Table 8. These down regulated target genes were enriched in complement and coagulation cascades, metabolic pathways, superpathway of tryptophan utilization, glycine biosynthesis and ion transport.

Validation of hub genes
To explore the prognostic role of up and down regulated hub genes, we analyzed the relationship between mRNA expression and overall survival (OS) using the UALCAN online tool. Interestingly, we found that high expression of TP53, PLK1, AURKA, CDK1 and ANLN were resulted in shorter OS in hepatoblastoma patients (Fig. 15), whereas low expression of ESR1, FGB, ACAT1, GOT1 and ALAS1 were resulted in shorter OS in hepatoblastoma patients (Fig. 16). To further validate the results, we examined the expression of ten hub genes using the UALCAN database. The expression levels of five up regulated hub genes (TP53, PLK1, AURKA, CDK1 and ANLN) and five down regulated hub genes (ESR1, FGB, ACAT1, GOT1 and ALAS1) were significantly different between hepatoblastoma samples and noncancerous liver samples (Fig. 17). The expression trends of the ten hub genes were consistent with the results we obtained. The stage analyses of TP53, PLK1, AURKA, CDK1, ANLN, ESR1, FGB, ACAT1, GOT1 and ALAS1 in human tissues were level of ESR1, FGB, ACAT1, GOT1 and ALAS1 were all positively associated with tumor purity . This finding further confirmed the key role of these up and down regulated hub genes probably expressed not in the microenvironment, but expressed in the tumor cells. These findings further confirmed the key role of these up and down regulated hub genes in the onset of hepatoblastoma.

Discussion
Presently, the speedy forward in microarray and high-throughput technologies has spread the function biomedicine in clinical practice, such as cancer initial diagnosis, new targeted drug exploration and prognosis prediction. GEO database, as a public repository for archiving high-throughput microarray experimental gene expression data, has contributed the dynamic tools to resolve important genes and pathways linked with the molecular pathogenesis of tumors [Wu et al. 2019]. In the current investigation, based on the GEO database, single gene expression profile including 53 hepatoblastoma tissues samples and 14 noncancerous liver tissue samples were integrated for a comprehensive bioinformatics analysis. The aim of our investigation was to identify the possible small molecule drugs for the treatment of hepatoblastoma and to determine the new biomarkers correspond with the molecular pathogenesis and prognosis of hepatoblastoma. A total of 996 DEGs between hepatoblastoma tissues and corresponding noncancerous liver tissues were diagnosed, which consisted of 499 up regulated genes and 497 down regulated genes. Genes such as DLK1 [Falix et al. 2012] and EPCAM (epithelial cell adhesion molecule) [Lopez-Nunez et al. 2019] were linked with development of hepatoblastoma. Genes such as NKD1 [Wang et al. 2017] and TNFRSF19  were liable for proliferation of hepatocellular carcinoma cells, but these genes may be linked with development of proliferation of hepatoblastoma cells. NPNT (nephronectin) was associated with invasion of breast cancer cells [Wang et al. 2018], but this gene may be responsible for invasion of hepatoblastoma cells. Decrease expression of tumour suppressor genes such as C3P1 [Zhong et al. 2018], SLC22A1 [Grimm et al. 2016], RDH16 [Zhu et al. 2020], HAO2 [Mattu et al. 2016] and GLS2 [Kuo et al. 2016] were linked with progression of hepatocellular carcinoma, but low expression of these genes may associated with invasion of hepatoblastoma cells.
In target genes -miRNA regulatory network analysis, we found out the top up regulated target genes. High expression of target genes such as PLAGL2 [Xu et al. 2018] andSLC1A5 [Toda et al. 2017] were involved in progression of various cancer types, but elevated expression of these genes may be associated with development of hepatoblastom. Our study found that PKM (pyruvate kinase M1/2) is up regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target. Similarly, target genes -miRNA regulatory network analysis, we found out the top down regulated target genes. Decreased expression of target genes such as SOD2 [Wang et al. 2016] andWEE1 [Cuneo et al. 2016] were liable for advancement of hepatocellular carcinoma, but reduced expression these genes may be involved in development of hepatoblastoma. Our study found that APOL6 is down regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target.
In target genes -TF regulatory network analysis, we found out the top up regulated target genes. Methylation inactivation of DCDC2 was responsible for progression of hepatocellular carcinoma [Inokawa et al. 2013], but loss of this gene may be liable for development of hepatoblastoma. Increase expression of DLX5 was important for proliferation of ovarian cancer cells [Tan et al. 2010], but this gene may be associated with proliferation of hepatoblastoma cells. Our study found that WFS1 is up regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target. Similarly, target genes -TF regulatory network analysis, we found out the top down regulated target genes. Our study found that SLC15A1 is down regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target.
Ten candidate genes (TP53, PLK1, AURKA, CDK1, ANLN, ESR1, FGB, ACAT1, GOT1 and ALAS1) that were closely related to the survival rate of patients with hepatoblastoma were diagonised by analyzing the corresponding total survival information from patients with hepatoblastoma from TCGA program. Survival analysis, expression verification, stage analysis, mutation analysis, immunio infiltration analysis and immunio histochemical analysis of these candidate genes were analyzed according to the TCGA database and the human protein atlas database. ROC analysis of these candidate genes were analyzed according to the GSE131329 dataset for prognostic and diagonsitic value of candidate genes. Semelateniously, these ten candidate genes were further verified by RT PCR using hepatoblastoma patient samples. Overall, the survival characteristics of the ten candidate genes may suggest the prognosis and diagnosis of hepatoblastoma, and thus may be a promising biomarker and therapeutic target for hepatoblastoma.
In summary, the current study used the GEO database, TCGA database and the human protein atlas database to diagonise ten candidate genes as possible biomarkers for patients with hepatoblastoma and documented the existence of the ten candidate genes by RT PCR. The results of the current study provide a potential biomarker for hepatoblastoma screening and diagnosis, therapeutic targets, and prognosis. However, further invedtigations and follow up of clinical cases are required to expose the molecular pathogenesis and prognosis of hepatoblastoma.

Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent
No informed consent because this study does not contain human or animals participants. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Availability of data and materials
The copyright holder for this this version posted December 26, 2020. ; preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  (2015)  Wang Y, Zhi Q, Ye Q, Zhou C, Zhang L, Yan W, Wu Q, Zhang D, Li P, Huo K (2016) SCYL1-BP1 affects cell cycle arrest in human hepatocellular carcinoma All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ; Wu Q, Zhang B, Sun Y, Xu R, Hu X, Ren S, Ma Q, Chen C, Shu J, Qi F et al (2019) Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis. Onco Targets  Ther 12: All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  (2015)  preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  TP53  CAGCACATGACGGAGGTTGT  TCATCCAAATACTCCACACGC  PLK1  AAAGAGATCCCGGAGGTCCTA  GGCTGCGGTGAATGGATATTTC  AURKA  GAGGTCCAAAACGTGTTCTCG  ACAGGATGAGGTACACTGGTTG  CDK1  AAACTACAGGTCAAGTGGTAGCC  TCCTGCATAAGCACATCCTGA  ANLN  TGCCAGGCGAGAGAATCTTC  CGCTTAGCATGAGTCATAGACCT  ESR1  CCCACTCAACAGCGTGTCTC  CGTCGATTATCTGAATTTGGCCT  FGB  AGTGATTCAGAACCGTCAAGAC  CATCCTGGTAAGCTGGCTAATTT  ACAT1  AAGGCAGGCAGTATTGGGTG  ACATCAGTTAGCCCGTCTTTTAC  GOT1  ATGGCACCTCCGTCAGTCT  AGTCATCCGTGCGATATGCTC  ALAS1 CGCCGCTGCCCATTCTTAT TCTGTTGGACCTTGGCCTTAG All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Probe Id
Gene Symbol logFC pValue adj.P.Val t value Regulation Gene Name All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ; preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020   preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ;https://doi.org/10.1101  All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020  preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020    preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020  preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ;https://doi.org/10.1101https://doi.org/10. /2020  preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.22.20248756 doi: medRxiv preprint Fig. 10. Modules in PPI network. The red nodes denote the down regulated genes Fig. 11. The network of up regulated genes and their related miRNAs. The green circles nodes are the up regulated genes, and blue diamond nodes are the miRNAs All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.22.20248756 doi: medRxiv preprint  preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10. 1101   preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10. 1101  All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10. 1101   All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.